(Q36429751)

14 August 2017

1 reference

title

Topiramate and its clinical applications in epilepsy (English)

1 reference

14 August 2017

Renzo Guerrini

1

1 reference

PubMed ID

16556095

14 August 2017

Lucio Parmeggiani

series ordinal

2

1 reference

PubMed ID

16556095

14 August 2017

language of work or name

English

0 references

publication date

1 April 2006

1 reference

Expert Opinion on Pharmacotherapy

14 August 2017

1 reference

14 August 2017

7

1 reference

14 August 2017

6

1 reference

14 August 2017

811-823

1 reference

Prevalence of epilepsy in Rochester, Minnesota: 1940-1980.

14 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

Some aspects of prognosis in the epilepsies: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

Pediatric epilepsy syndromes: an update and critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

Topiramate attenuates voltage-gated sodium currents in rat cerebellar granule cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

Frequency-dependent inhibition of neuronal activity by topiramate in rat hippocampal slices

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

Effects of nicardipine, an antagonist of L-type voltage-dependent calcium channels, on kindling development, kindling-induced learning deficits and hippocampal potentiation phenomena.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

L-type Ca(2+) channel blocker inhibits mossy fiber sprouting and cognitive deficits following pilocarpine seizures in immature mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

Two new actions of topiramate: inhibition of depolarizing GABA(A)-mediated responses and activation of a potassium conductance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

KCNQ2 and KCNQ3 potassium channel genes in benign familial neonatal convulsions: expansion of the functional and mutation spectrum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

The pharmacologic basis of antiepileptic drug action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

Cellular electrophysiology of human epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

Proton inhibition of N-methyl-D-aspartate receptors in cerebellar neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

Proton sensitivity of the GABA(A) receptor is associated with the receptor subunit composition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

Single-dose pharmacokinetics and effect of food on the bioavailability of topiramate, a novel antiepileptic drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

Relative bioavailability of topiramate administered rectally

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

A pharmacological and clinical review on topiramate, a new antiepileptic drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

Topiramate kinetics during delivery, lactation, and in the neonate: preliminary observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

Influence of dosage, age, and co-medication on plasma topiramate concentrations in children and adults with severe epilepsy and preliminary observations on correlations with clinical response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

Randomized, concentration-controlled trial of topiramate in refractory focal epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

Topiramate serum concentration-to-dose ratio: influence of age and concomitant antiepileptic drugs and monitoring implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

Cytochrome P450 isozymes and antiepileptic drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

Valproate-induced hyperammonemic encephalopathy in the presence of topiramate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

Topiramate and lamotrigine pharmacokinetics during repetitive monotherapy and combination therapy in epilepsy patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

Low-dose topiramate in adults with treatment-resistant partial-onset seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children. Topiramate YP Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

Effectiveness, tolerability, and safety of topiramate in children with partial-onset seizures. Topiramate YP Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

Preliminary observations on topiramate in pediatric epilepsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

Topiramate in Lennox-Gastaut syndrome: open-label treatment of patients completing a randomized controlled trial. Topiramate YL Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

Topiramate monotherapy for partial onset seizures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

A dose-comparison trial of topiramate as monotherapy in recently diagnosed partial epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

Topiramate on ictal seizure semiology: a quantitative, randomized, low and medium dose-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

Clinical effects of topiramate against secondarily generalized tonic--clonic seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

Topiramate in the long-term management of refractory epilepsy. Topiramate YOL Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

An overview of the efficacy and tolerability of new antiepileptic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

Topiramate: efficacy and tolerability in children according to epilepsy syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

Topiramate as add-on drug in severe myoclonic epilepsy in infancy: an Italian multicenter open trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

Topiramate as add-on drug in children, adolescents and young adults with Lennox-Gastaut syndrome: an Italian multicentric study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

Topiramate monotherapy as broad-spectrum antiepileptic drug in a naturalistic clinical setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

A pilot study of topiramate in the treatment of infantile spasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

Topiramate monotherapy for childhood absence seizures: an open label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

Role of topiramate in adults with intractable epilepsy, mental retardation, and developmental disabilities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

Topiramate in long-term treatment of epilepsy in the intellectually disabled

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

The use of topiramate in refractory status epilepticus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

Postmarketing experience with topiramate and cognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

Differential cognitive and behavioral effects of topiramate and valproate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

Effects of topiramate on cognitive function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

The effects of adjunctive topiramate on cognitive function in patients with epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

Reversible language regression as an adverse effect of topiramate treatment in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

An audit of topiramate use in a general neurology clinic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

Topiramate and psychiatric adverse events in patients with epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

Drug induced encephalopathy in six epileptic patients: topiramate? valproate? or both?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

Reversible hemiparesis associated with the use of topiramate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

Electrophysiological characterization of spontaneous and carbamazepine-induced epileptic negative myoclonus in benign childhood epilepsy with centro-temporal spikes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

Topiramate increases biochemical risk of nephrolithiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

Topiramate and metabolic acidosis in pediatric epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

Adverse ocular drug reactions recently identified by the National Registry of Drug-Induced Ocular Side Effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

Acute myopia and angle-closure glaucoma induced by topiramate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

Mechanism of topiramate-induced acute-onset myopia and angle closure glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

Topiramate and metabolic acidosis in infants and toddlers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

Metabolic concerns associated with antiepileptic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

Effect of topiramate on body weight and body composition of osborne-mendel rats fed a high-fat diet: alterations in hormones, neuropeptide, and uncoupling-protein mRNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

Transient hypohidrosis induced by topiramate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

The effects of adjunctive topiramate therapy on seizure severity and health-related quality of life in patients with refractory epilepsy---a Canadian study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

Oligohydrosis and hyperthermia: pilot study of a novel topiramate adverse effect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.6.811

21 January 2018

Identifiers

DOI

10.1517/14656566.7.6.811

1 reference

14 August 2017

1 reference

PubMed ID

16556095